

CytoTools AG substantially increases its majority holding in the successful subsidiary DermaTools Biotech GmbH

- Biotech company now holds almost 60% of DermaTools Biotech GmbH
- Capital increase secures the further clinical development of DermaPro® in Europe

Darmstadt, March 22, 2012 – CytoTools AG, a technology holding company with investments in the fields of pharmaceuticals and medical products, has substantially increased its stake in the subsidiary DermaTools Biotech GmbH. As part of a capital increase, CytoTools AG has boosted its stake in DermaTools Biotech GmbH from 51% to about 60%. This allows the company to continue to support the successful clinical developments of the subsidiary. DermaTools Biotech GmbH received a cash inflow of over EUR 2.0 million from the capital increase to a share capital of EUR 111,000. These funds are primarily being used for the planned start of the clinical phase III study during the course of this year.

By subscribing further shares, CytoTools is using the funds gained from its own capital increase at the end of last year as planned. This achieves the target of substantially boosting its own shareholder position within DermaTools and driving progress in the clinical development of the subsidiary. This move also significantly boosts liquidity for DermaTools Biotech GmbH. The basis is therefore now in place for a continuation of the successful development programme given the completion of the treatment of the last patients at the German centres and the progress of the data evaluation.

For regulatory reasons and to ensure comprehensive publication, DermaTools has decided to complete the treatment of the final patients in the Baltic centres before a full evaluation and publication of the study's findings are released. This ensures that the effectiveness of the dataset which is key to applying for the phase III study is not compromised. In contrast to previous planning, country-specific unblinding will only take place after the completion of the phase IIb study. The treatment of the final patients in the Baltic centres will be completed in Q2. With the expected positive study evaluation, there is now nothing standing in the way of achieving the central goal of launching the European phase III this year.

This release contains specific future-oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.

PRESS INFORMATION



CytoTools

Company information:

CytoTools AG, previously CytoTools GmbH, is a technology and holding company which holds the following shares in its subsidiaries which carry out product development in the pharmaceutical and medical products field: ~60% in DermaTools Biotech GmbH (therapy field dermatology, urology) and 46% in CytoPharma GmbH (therapy field cardiovascular disease, cancer). The complete know-how is protected by corresponding basic patents which are maintained worldwide by CytoTools AG and transferred to the subsidiary companies in the form of exclusive licenses.

Kontakt:

CytoTools AG
Dr. Mark Andre Freyberg
Klappacher Str. 126
64285 Darmstadt
Tel.: +49-6151-95158-12
Fax: +49-6151-95158-13
E-Mail: freyberg@cytotools.de

Pressekontakt:

cometis AG
Ulrich Wiehle
Unter den Eichen 7
65195 Wiesbaden
Tel.: +49-611-205855-11
Fax: +49-611-205855-66
E-Mail: wiehle@cometis.de